Humanized mice for the development and testing of human vaccines

Expert Opinion on Drug Discovery

Volumn 2, Issue 7, 2007, Pages 949-960

  Aspord, Caroline ^a   Yu, Chun I ^a   Banchereau, Jacques ^a   Palucka, A Karolina ^b  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

CD34 HPC; Humanized mice; Immune system; Immunotherapy; Vaccine

Indexed keywords

HLA ANTIGEN; LEUKOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE MODEL; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INFLUENZA; LYMPHOID ORGAN; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; NUDE MOUSE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; SCID MOUSE; T LYMPHOCYTE; TRANSGENIC MOUSE; XENOGRAFT;

EID: 34547473029     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.7.949     Document Type: Review

References (83)

1. SHORTMAN K, LIU YJ: Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. (2002) 2:151-161.
2. BRIGL M, BRENNER MB: CD1: antigen presentation and T cell function. Annu. Rev. Immunol. (2004) 22:817-890.
3. CERWENKA A, LANIER LL: Natural killer cells, viruses and cancer. Nat. Rev. Immunol. (2001) 1:41-49.
4. MESTAS J, HUGHES CC: Of mice and not men: differences between mouse and human immunology. J. Immunol. (2004) 172:2731-2738.
5. MOSIER DE, GULIZIA RJ, BAIRD SM, WILSON DB: Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature (1988) 335:256-259.
6. MCCUNE JM: The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science (1988) 241:1632-1639.
7. KAMEL-REID S, DICK JE: Engraftment of immune-deficient mice with human hematopoietic stem cells. Science (1988) 242:1706-1709.
8. SHULTZ LD, ISHIKAWA F, GREINER DL: Humanized mice in translational biomedical research. Nat. Rev. Immunol. (2007) 7:118-130.
9. SANJEEVI CB: Genes influencing innate and acquired immunity in type 1 diabetes and latent autoimmune diabetes in adults. Ann. NY Acad. Sci. (2006) 1079:67-80.
10. GORONZY JJ, WEYAND CM: Rheumatoid arthritis. Immunol. Rev. (2005) 204:55-73.
11. PRICE P, WITT C, ALLCOCK R et al.: The genetic basis for the association of the 8.1 ancestral haplotype (A1, BS, DR3) with multiple immunopathological diseases. Immunol. Rev. (1999) 167:257-274.
12. FROHMAN EM: Multiple sclerosis. Med. Clin. North Am. (2003) 87:867-897, viii-ix.
13. TANEJA V, DAVID CS: HLA transgenic mice as humanized mouse models of disease and immunity. J. Clin. Invest. (1998) 101:921-926.
14. TANEJA V, BEHRENS M, MANGALAM A et al.: New humanized HLA-DR4-transgenic mice that mimic the sex bias of rheumatoid arthritis. Arthritis Rheum. (2007) 56:69-78.
15. HAMMER RE, MAIKA SD, RICHARDSON JA, TANG JP, TAUROG JD: Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m: an animal model of HLA-B27-associated human disorders. Cell (1990) 63:1099-1112.
16. NABOZNY GH, BAISCH JM, CHENG S et al.: HLA-DQ8 transgenic mice are highly susceptible to collagen-induced arthritis: a novel model for human polyarthritis. J. Exp. Med. (1996) 183:27-37.
17. DAS P, DRESCHER KM, GELUK A et al.: Complementation between specific HLA-DR and HLA-DQ genes in transgenic mice determines susceptibility to experimental autoimmune encephalomyelitis. Hum. Immunol. (2000) 61:279-289.
18. ABRAHAM RS, KUDVA YC, WILSON SB, STROMINGER JL, DAVID CS: Co-expression of HLA DR3 and DQ8 results in the development of spontaneous insulitis and loss of tolerance to GAD65 in transgenic mice. Diabetes (2000) 49:548-554.
19. RAJU R, ZHAN WZ, KARACHUNSKI P et al.: Polymorphism at the HLA-DQ locus determines susceptibility to experimental autoimmune myasthenia gravis. J. Immunol. (1998) 160:4169-4174.
20. PAJOT A: A mouse model of human adaptive immune functions: HLA-A2.1-/ HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur. J. Immunol. (2004) 34:3060-3069.
21. FUGGER L, MICHIE SA, RULIFSON I, LOCK CB, MCDEVITT GS: Expression of HLA-DR4 and human CD4 transgenes in mice determines the variable region β-chain T-cell repertoire and mediates an HLA-DR-restricted immune response. Proc. Natl. Acad. Sci. USA (1994) 91:6151-6155.
22. GELUK A, TANEJA V, VAN MEIJGAARDEN KE et al.: Identification of HLA class II-restricted determinants of Mycobacterium tubereulosis-derived proteins by using HLA-transgenic, class II-deficient mice. Proc. Natl. Acad. Sci. USA (1998) 95:10797-10802.
23. BOTTEN J, ALEXANDER J, PASQUETTO V et al.: Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J. Virol. (2006) 80:8351-8361.
24. MACHLENKIN A, AZRIEL-ROSENFELD R, VOLOVITZ I et al.: Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunol. Immunother. (2007) 56:217-226.
25. OKAZAKI T: Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice. J. Virol. (2006) 80:10645-10651.
26. PASCOLO S: HLA class I transgenic mice: development, utilization and improvement. Expert Opin. Biol. Ther. (2005) 5:919-938.
27. STREET MD, DOAN T, HERD KA, TINDLE RW: Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein. Immunology (2002) 106:526-536.
28. BOSMA GC, CUSTER RP, BOSMA MJ: A severe combined immunodeficiency mutation in the mouse. Nature (1983) 301:527-530.
29. TARY-LEHMANN M, SAXON A, LEHMANN PV: The human immune system in hu-PBL-SCID mice. Immunol. Today (1995) 16:529-533.
30. IFVERSEN P, BORREBAECK CA: SCID-Hu-PBL: a model for making human antibodies? Semin. Immunol. (1996) 8:243-248.
31. SANDHU J, SHPITZ B, GALLINGER S, HOZUMI N: Human primary immune response in SCID mice engrafted with human peripheral blood lymphocytes. J. Immunol. (1994) 152:3806-3813.
32. COCCIA MA, BRAMS P: High titer, prostate specific antigen-specific human IgG production by hu-PBL-SCID mice immunized with antigen-mouse IgG2a complex-pulsed autologous dendritic cells. J. Immunol. (1998) 161:5772-5780.
33. GARCIA S, DADAGLIO G, GOUGEON ML: Limits of the human-PBL-SCID mice model: severe restriction of the Vβ T-cell repertoire of engrafted human T cells. Blood (1997) 89:329-336.
34. SAXON A: Limited B cell repertoire in severe combined immunodeficient mice engrafted with peripheral blood mononuclear cells derived from immunodeficient or normal humans. J. Clin. Invest. (1991) 87:658-665.
35. DUCHOSAL MA, EMING SA, MCCONAHEY PJ, DIXON FJ: Characterization of hu-PBL-SCID mice with high human immunoglobulin serum levels and graft-versus-host disease. Am. J. Pathol. (1992) 141:1097-1113.
36. WILLIAMS SS, UMEMOTO T, KIDA H, REPASKY EA, BANKERT RB: Engraftment of human peripheral blood leukocytes into severe combined immunodeficient mice results in the long term and dynamic production of human xenoreacrive antibodies. J. Immunol. (1992) 149:2830-2836.
37. + T cells. Immunology (1994) 83:171-179.
38. BANUELOS SJ, SHULTZ LD, GREINER DL et al.: Rejection of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive human lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1(null) mice. Clin. Immunol. (2004) 112:273-283.
39. BANKERT RB, EGILMEZ NK, HESS SD: Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol. (2001) 22:386-393.
40. MOSIER DE: Viral pathogenesis in hu-PBL-SCID mice. Semin. Immunol. (1996) 8:255-262.
41. DUCHOSAL MA, MCCONAHEY PJ, ROBINSON CA, DIXON FJ: Transfer of human systemic lupus erythematosus in severe combined immunodeficient (SCID) mice. J. Exp. Med. (1990) 172:985-988.
42. SAEKI Y: Transfer of multiple sclerosis into severe combined immunodeficiency mice by mononuclear cells from cerebrospinal fluid of the patients. Proc. Natl. Acad. Sci. USA (1992) 89:6157-6161.
43. LAPENTA C: Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-α. J. Exp. Med. (2003) 198:361-267.
44. + cytotoxic T lymphocytes protect human peripheral blood leukocyte-severe combined immunodeficient mice from HIV-1 infection by an HLA-unrestricted mechanism. J. Immunol. (1994) 153:4826-4833.
45. OKADA M: The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice. Vaccine (2005) 23:2269-2272.
46. MACCHIARINI F, MANZ MG, PALUCKA AK, SHULTZ LD: Humanized mice: are we there yet? J. Exp. Med. (2005) 202:1307-1311.
47. MOSIER DE, STELL KL, GULIZIA RJ, TORBETT BE, GILMORE GL: Homozygous scid/ scid;beige/beige mice have low levels of spontaneous or neonatal T cell-induced B cell generation. J. Exp. Med. (1993) 177:191-194.
48. YACOUB-YOUSSEF H: Engraftment of human T, B and NK cells in CB.17 SCID/ beige mice by transfer of human spleen cells. Transpl. Immunol. (2005) 15:157-164.
49. LORBER MI: Human allogeneic vascular rejection after arterial transplantation and peripheral lymphoid reconstitution in severe combined immunodeficient mice. Transplantation (1999) 67:897-903.
50. MARCHEIX B: Multiple human mesenteric arterial grafts from the same donor to study human chronic vascular rejection in humanized SCID/beige mice. J. Heart Lung Transplant. (2006) 25:675-682.
51. MOSIER DE, PICCHIO GR, BAIRD SM, KOBAYASHI R, KIPPS TJ: Epstein-Barr virus-induced human B-cell lymphomas in SCID mice reconstituted with human peripheral blood leukocytes. Cancer Res. (1992) 52:s5552-s5553.
52. RONCAROLO MG, CARBALLIDO JM, ROULEAU M, NAMIKAWA R, DE VRIES JE: Human T-and B-cell functions in SCID-hu mice. Semin. Immunol. (1996) 8:207-213.
53. VANDEKERCKHOVE BA: Human Ig production and isotype switching in severe combined immunodeficient-human mice. J. Immunol. (1993) 151:128-137.
54. NAMIKAWA R, WEILBAECHER KN, KANESHIMA H, YEE EJ, MCCUNE JM: Long-term human hematopoiesis in the SCID-hu mouse. J. Exp. Med. (1990) 172:1055-1063.
55. KYOIZUMI S: Implantation and maintenance of functional human bone marrow in SCID-hu mice. Blood (1992) 79:1704-1711.
56. VANDEKERCKHOVE BA, KROWKA JF, MCCUNE JM et al.: Clonal analysis of the peripheral T cell compartment of the SCID-hu mouse. J. Immunol. (1991) 146:4173-4179.
57. CARBALLIDO JM, NAMIKAWA R, CARBALLIDO-PERRIG N et al.: Generation of primary antigen-specific human T- and B-cell responses in immunocompetent SCID-hu mice. Nat. Med. (2000) 6:103-106.
58. ROULEAU M, NAMIKAWA R, ANTONENKO S, CARBALLIDO-PERRIG N, RONCAROLO MG: Antigen-specific cytotoxic T cells mediate human fetal pancreas allograft rejection in SCID-hu mice. J. Immunol. (1996) 157:5710-5720.
59. MCCUNE J: The SCID-Hu mouse: a small animal model for HIV infection and pathogenesis. Annu. Rev. Immunol. (1991) 9:399-429.
60. MELKUS MW: Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. (2006) 12:1316-1322.
61. + T cell depletion in humanized mice infected with HIV-1. J. Exp. Med. (2007) 204:705-714.
62. -/- mice. Ann. NY Acad. Sci. (2005) 1044:236-243.
63. LEGRAND N, WEIJER K, SPITS H: Experimental models to study development and function of the human immune system in vivo. J. Immunol. (2006) 176:2053-2058.
64. VORMOOR J: Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immunodeficient mice. Blood (1994) 83:2489-2497.
65. CASHMAN JD: Kinetic evidence of the regeneration of multilineage hematopoiesis from primitive cells in normal human bone marrow transplanted into immunodeficient mice. Blood (1997) 89:4307-4316.
66. LAPIDOT T: Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice. Science (1992) 255:1137-1141.
67. SHULTZ LD: Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. (1995) 154:180-191.
68. + cells in nonobese diabetic/Shi-scid, IL-2 receptor γ null mice. J. Immunol. (2002) 169:204-209.
69. ITO M: NOD/SCID/γ(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood (2002) 100:3175-3182.
70. SHULTZ LD: Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R γ null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. (2005) 174:6477-6489.
71. ISHIKAWA F: Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chain(null) mice. Blood (2005) 106:1565-1573.
72. TRAGGIAI E: Development of a human adaptive immune system in cord blood cell-transplanted mice. Science (2004) 304:104-107.
73. BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392:245-252.
74. + hematopoietic progenitors. Blood (2003) 102:3302-3310.
75. WATANABE S: Hematopoietic stem cell-engrafted NOD/SCID/IL2Rγ null mice develop human lymphoid system and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood (2007) 109:212-218.
76. + cells using the NOD/SCIDγc null mice model. Blood (2003) 102:873-880.
77. -/- mice. Proc. Natl. Acad. Sci. USA (2006) 103:15951-15956.
78. + cell transplantation. Blood (2006) 108:487-492.
79. BENTE DA, MELKUS MW, GARCIA JV, RICO-HESSE R: Dengue fever in humanized NOD/SCID mice. J. Virol. (2005) 79:13797-13799.
80. + cells with Epstein-Barr virus. J. Virol. (2004) 78:13891-13900.
81. + T cells that facilitate tumor development. J. Exp. Med. (2007) 204:1037-1047.
82. GREGERSEN JW, HOLMES S, FUGGER L: Humanized animal models for autoimmune diseases. Tissue Antigens (2004) 63:383-394.
83. -/- mice: functional inactivation of p53 in developing T cells. Blood (2004) 104:3886-3893.